Compare MIGI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | INDP |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.5M |
| IPO Year | 2013 | 2021 |
| Metric | MIGI | INDP |
|---|---|---|
| Price | $2.60 | $1.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.1K | 21.0K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.90 | 12.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,571,720.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.27 |
| 52 Week High | $15.80 | $13.24 |
| Indicator | MIGI | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 40.75 |
| Support Level | $0.36 | $1.65 |
| Resistance Level | $3.50 | $2.18 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 14.29 | 18.30 |
Mawson Infrastructure Group Inc is a digital infrastructure provider with diversified operations across Cryptocurrency Mining and Digital Asset Management. Its mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a focus on shareholder returns. The Company has three primary businesses: digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. It operates in a single segment surrounding its digital currency mining operation.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.